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Chemokines are thought to play an important part in
the development of inflammation in atopic dermatitis.
Eotaxin, a CC chemokine, is a potent chemoattractant
and activator of human eosinophils, basophils and Th2
lymphocytes which acts via the chemokine receptor
CCR3. We studied the expression of eotaxin and
CCR3, as well as MCP-3, MIP-1a and interleukin-8,
in atopic dermatitis and normal skin by immunohisto-
chemistry and nested reverse transcriptase–polymerase
chain reaction. Skin biopsy specimens were obtained
from nonlesional and lesional skin of patients with
atopic dermatitis and of nonatopic controls. Immuno-
reactivity and transcripts of eotaxin and CCR3 were
significantly increased in lesional skin from atopic
Atopic dermatitis (AD) is a chronic, relapsing inflam-matory skin disease which is characterized by extremepruritus, typically distributed eczematous skin lesionsand a personal or family history of atopic diseases(Beltrani, 1996). It is often associated with increased
serum immunoglobulin E levels and blood eosinophilia. Although
the pathogenesis of AD is poorly understood, immunologic
mechanisms are thought to be involved (Leung and Hamid, 1996).
The skin lesions of AD reveal a mononuclear cell infiltrate,
mainly consisting of CD41 T lymphocytes (Braathen et al, 1979),
are infiltrated by eosinophils and show extensive deposition of
eosinophil granule proteins in the dermis (Leiferman and Gleich,
1996). The chemotactic signals responsible for the recruitment of
these proinflammatory cells into the skin lesions, however, have
not yet been fully elucidated.
Previous reports suggest that chemokines are involved in
modulating tissue inflammation (Schro¨der et al, 1996; Baggiolini
et al, 1997). Chemokines represent a family of 8–10 kDa basic
heparin-binding polypeptide mediators, which are important for
selective leukocyte recruitment. According to the position of the
first two cysteines two main subfamilies (CXC and CC) are
distinguished. Eotaxin, a CC chemokine, is a potent chemo-
attractant and activator of eosinophils (Ponath et al, 1996b) and
basophils (Uguccioni et al, 1997; Yamada et al, 1997). In addition,
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dermatitis, but not in nonatopic controls. In non-
lesional atopic dermatitis samples CCR3 expression
was also significantly increased at the mRNA and
protein level, whereas eotaxin was increased at the
mRNA level only. No significant difference in the
expression of MCP-3, MIP-1a, and interleukin-8 was
observed between skin samples from atopic dermatitis
and nonatopic controls. The enhanced local produc-
tion of eotaxin may lead to the recruitment of eosino-
phils and T lymphocytes, which both express CCR3
and contribute to the initiation and maintenance of
inflammation. Key words: atopic dermatitis/CCR3/
eotaxin/immunohistochemistry/reverse transcriptase–poly-
merase chain reaction. J Invest Dermatol 113:43–48, 1999
recent reports suggest that it also is a main attractant for Th2
lymphocytes (Gerber et al, 1997; Sallusto et al, 1997). Eotaxin is
produced by various cell types including eosinophils, lymphocytes,
macrophages, chondrocytes, fibroblasts, smooth muscle cells, and
endothelial and epithelial cells (Bartels et al, 1996; Kitaura et al,
1996; Ponath et al, 1996a; Lamkhioued et al, 1997; Mattoli et al,
1997; Minshall et al, 1997; Ying et al, 1997; Luster, 1998). The
activities of eotaxin are mediated by binding to the chemokine
receptor CCR3, that is expressed on eosinophils (Daugherty et al,
1996; Ponath et al, 1996), basophils (Uguccioni et al, 1997),
dendritic cells (Rubbert et al, 1998), and Th2 lymphocytes (Gerber
et al, 1997; Sallusto et al, 1997). So far no information on the
possible involvement of eotaxin and CCR3 in AD is available.
This study was therefore designed to investigate in situ the expression
of eotaxin and the CCR3 receptor in nonlesional and lesional skin
of patients with chronic AD. Furthermore, we sought to examine
the expression of several other chemokines such as MCP-3, MIP-
1α, and interleukin (IL)-8, which have previously been reported
to be involved in the recruitment of proinflammatory cells (Ying
et al, 1995; Bacon and Schall, 1996).
MATERIALS AND METHODS
Subjects and skin specimens The Ethical Committee of the Medical
Faculty of the University of Bern approved the study. Twenty-six caucasian
patients with moderate to severe chronic AD and 11 nonatopic controls
were included in the study after obtaining their informed consent. The
clinical and laboratory characteristics of the study population are shown in
Table I. AD was diagnosed according to the criteria of Hanifin and Rajka
(Hanifin and Rajka, 1980). Clinical severity of AD was documented by
the scoring AD (SCORAD) index as described previously (Kunz et al,
1997). The patients did not receive any systemic corticosteroids or topical
treatment with corticosteroids at the site where biopsy specimens were
obtained for at least 3 wk prior to the investigation. Punch biopsy specimens
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Table I. Clinical details of the nonatopic controls with NS and AD patients with NL and LS
Type of skin lesions Patients Age range Gender (F/M) SCORAD index Blood eosinophils (%) Immunoglobulin E (KU per l)
NS n 5 11 22–60 6/5 0 0–3% 2–80
NL n 5 13 21–52 6/7 32–88 2–16% 172–2150
LS n 5 13 17–59 7/6 25–99 3.5–17% 190–1850
of 5 mm diameter were taken from 13 patients with chronic eczematous
skin lesions in the large joint flexures. In 13 additional patients biopsy
specimens were taken from nonlesional skin located about 10 cm from a
chronic eczematous skin lesions. Normal skin from 11 nonatopic controls
was obtained from patients undergoing plastic reconstructive surgery. The
material was snap-frozen in tissue embedding medium using isopentane
precooled in liquid nitrogen and stored at –70°C.
Immunohistochemistry Immunostaining of skin sections from AD
skin lesions (n 5 7), AD nonlesional skin (n 5 7), and normal skin
(n 5 5) was performed using the alkaline phosphatase antialkaline phosphatase
(APAAP) method (Ulfgren et al, 1995). Briefly, 6 µm cryostat tissue sections
were fixed in 4% formaldehyde. The sections were incubated overnight
with one of the following monoclonal antibodies: anti-eotaxin (clone
6H9), anti-CCR3 (clone 7B11), anti-MCP-3 (clone 9H11), anti-MIP-1α
(clone 11A3) and anti-IL-8 (clone A2A) all at 5 µg per ml (kindly
provided by LeukoSite Inc., Cambridge, MA); anti-MBP (1:20, BMK13,
ImmunoKontact), and anti-CD3 (1:50; M756, DAKO, Glostrup, DK).
Isotype-matched immunoglobulins were used as negative controls. In
addition, the specificity of the antigen–antibody reaction was tested by
preabsorption of the antibody with excess antigen. After washing, the
sections were incubated with a rabbit anti-mouse antibody (dilution 1:50;
Z259; DAKO) and the APAAP complexes (dilution 1:50; D651; DAKO).
To enhance the signal, the incubation with the rabbit anti-mouse antibody
and the APAAP complexes was repeated. Finally, the sections were
developed in New Fuchsin (DAKO Glostrup, DK) and counterstained
with hematoxylin. Skin sections were also fixed in 4% formalin and stained
with hematoxylin and eosin for standard histologic examination. The slides
were analyzed with a Leitz Dialux 20EB microscope by three independent
investigators. In each section, staining was assessed on 10–15 adjacent fields
at 4003 magnification. The positive cells were counted using a 0.09 mm2
grid and the number of positive cells (mean 6 SEM) per mm2 was
calculated. Only positively stained cells with a nucleus were included in
the counting. Statistical analysis was performed using the Mann–Whitney
U-test.
Reverse transcriptase–polymerase chain reaction Skin biopsy speci-
mens were homogenized and total RNA was extracted from AD skin
lesions (n 5 6), AD nonlesional skin (n 5 6), and normal skin (n 5 6)
using the SV40 total RNA isolation kit (Promega, Madison, WI). The RNA
isolation method included a digestion step for DNA. RNA isolated from the
melanoma SB-1 cell line (kindly obtained from B.C. Giovanella, Stehlin
Foundation for Cancer Research, Houston, TX) served as a negative
control. The total amount of RNA was quantitated by spectrophotometry.
Aliquots of 200 ng of total RNA were reverse transcribed and the
cDNA amplified using the Promega one-tube/two-enzymes Access reverse
transcriptase–polymerase chain reaction (reverse transcriptase–PCR) system
following the manufacturer’s instructions. To enhance sensitivity and
specificity of the reaction, a nested PCR was performed with primers for
eotaxin (intron-spanning) and for CCR3 as described previously (Bartels
et al, 1996) and based on the published sequences of human eotaxin and
CCR3 cDNA (Daugherty et al, 1996; Garcia-Zepeda et al, 1996). The
primers chosen for CCR3 amplify the transmembrane domain of the
receptor that shows the least homology to other chemokine receptors. The
sequences of PCR primers used for amplification were as follows (listed
59-39): eotaxin (sense/primer 1, position: 55–69) TGAAGGTCC-
CTCCGCAGCACTTCTGTG (anti-sense/primer 2, position: 320–344)
TGGCTTTGGAGTTGGAGATTTTTGG (sense, internal primer 3 in
the nested PCR, position: 137–161) CCCAACCACCTGCTGC-
TTTAACCTG; CCR3 (sense/primer 1, position: 246–265) ATCCTAC-
TATGATGACGTGG (anti-sense/primer 2, position: 690–709) ATTC-
AGGAAGAGCTGCTAGC (sense, internal primer 3 in the nested PCR,
position: 281–300) AAGCTGATACCAGAGCACTG; β-actin (sense)
ATCTGGCACCACACCTTCTACAATGAGCTGCG (anti-sense) CG-
TCATACTCCTGCTTGCTGATCCACATCTGC. The predicted sizes
of the PCR products are as follow: eotaxin 289 bp, eotaxin nested 208 bp;
CCR3 463 bp, CCR3 nested 429 bp, β-actin 838 bp. The reaction was
carried out in a thermocycler (GeneAmp PCR system 9600, Perkin Elmer)
and consisted of 20 cycles of denaturation at 94°C for 20 s, annealing at
52°C for 20 s and extension at 72°C for 30 s. The ‘‘nested’’ second round
of PCR was performed using an internal primer along with one of the
original primers and was carried out for 28 cycles. Amplification of β-
actin was used as an internal control. In preliminary experiments PCR
cycle numbers, primer, and mRNA concentrations were optimized to
obtain a linear range of signal strength, which was found between 25 and
30 rounds of thermal cycling in the second step of amplification. For each
experiment, internal controls lacking template were performed and shown
to be negative. In addition, PCR with total RNA as template to check
for DNA contamination revealed no amplification. PCR products were
analyzed by electrophoresis on a 2% agarose gel and visualized by ethidium
bromide staining. The size of the amplified products was compared with
molecular weight markers run in parallel. The exposed films obtained from
the gels were evaluated with an optometric scanner and the integrated
optical density in arbitrary units was determined. The levels of eotaxin and
CCR3, relative to the β-actin control, were calculated and the results
expressed as relative amounts of mRNA. Furthermore, PCR products of
eotaxin and CCR3 were sequenced by Microsynth (Belgach, Switzerland)
to confirm the specificity of the reaction.
RESULTS
Eotaxin and CCR3 immunoreactivity is associated with
enhanced infiltration of eosinophils in AD Histologic
examination of hematoxylin and eosin stained sections from AD
demonstrated a varying degree of acanthosis and a predominantly
perivascular lymphocyte infiltration of the superficial dermis.
Increased numbers of eosinophils and T lymphocytes were found
in the lesional AD skin sections (11.6 6 1.7 per mm2 and
124.7 6 21.7 per mm2) as compared with nonlesional AD
(1.7 6 2.4 per mm2 and 40.5 6 8.7 per mm2) and normal skin
samples (1.6 6 1.0 per mm2 and 10.0 6 3.5 per mm2). In
addition, enhanced immunostaining of major basic protein scattered
throughout the dermis was also seen in lesional AD skin (data not
shown). Using well characterized antibodies (Ponath et al, 1996b;
Xia et al, 1998), eotaxin and CCR3 immunoreactivity was mainly
found in a few mononuclear cells in normal skin (Fig 1a, b). In
nonlesional AD skin an enhanced expression was observed for
CCR3, whereas immunoreactivity for eotaxin was only slightly
stronger than that of normal skin (data not shown). In contrast to
normal skin and nonlesional AD skin, a pronounced enhancement
of eotaxin and CCR3 expression was observed in lesional skin
from AD (Fig 1c, d). Eotaxin and CCR3 staining was predominantly
present in mononuclear cells of the dermis. As double immuno-
staining experiments were not feasible, staining of serial sections
was performed which suggest that CD31 cells (Fig 1e) express
these proteins. No positive staining was observed when the primary
antibody was substituted with an isotype-matched immunoglobulin
G (Fig 1f ) or when preabsorbed antibodies were used (data not
shown). Furthermore, the different types of cells expressing eotaxin
are shown in Fig 2. Besides mononuclear cells (Fig 2a), fibroblasts
(Fig 2b), and eosinophils (Fig 2c), which were identified by their
typical morphology showed eotaxin immunoreactivity.
Quantitation and statistical analysis of eotaxin and CCR3
immunoreactivity is shown in Fig 3. A significant increase
(p , 0.05) in the number of positive cells for eotaxin was found
in lesional skin (LS) as compared with normal skin (NS) and
nonlesional skin (NL). No significant increase in eotaxin immuno-
reactivity was found between normal skin (NS) and nonlesional
skin (NL). For CCR3 a significant enhancement (p , 0.05) of
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Figure 1. Eotaxin and CCR3 immunoreactivity in AD and normal skin. Serial skin sections from one patient with AD and one nonatopic control
are shown as representative examples. Few eotaxin-positive (a) and CCR3-positive (b) cells are detected in the dermis of normal skin. In contrast, an
increased number positive cells for eotaxin (c) and CCR3 (d) was observed in the dermis of AD skin lesions. CD31 cells (e) and a negative control stained
with an isotype-matched immunoglobulin G (f) are also shown. Scale bars: (a, b) 45 µm, (c–f) 55 µm.
Figure 2. Immunoreactivity for
eotaxin. Located in mononuclear cells (a),
fibroblasts (b) and eosinophils (c). Scale bars:
5.7 µm.
immunoreactivity was detected in nonlesional as compared with
normal skin, which was further significantly increased in lesional
skin. No significant differences were found for MCP-3 (NS:
6.3 6 2.3 per mm2, NL: 7.0 6 2.0 per mm2, LS: 9.9 6 4.0 per
mm2), MIP-1α (NS: 12.1 6 2.8 per mm2, NL: 19.0 6 5.4
per mm2, LS: 26.0 6 16.7 per mm2), and IL-8 (NS: 12.5 6 4.6
per mm2, NL: 17.2 6 8.1 per mm2, LS: 32.9 6 17.9 per mm2),
although a tendency for a stronger immunoreactivity was also
observed for these cytokines in lesional AD skin.
Eotaxin and CCR3 mRNA levels are elevated in AD To
determine whether eotaxin and CCR3 expression are also enhanced
at the mRNA level in AD, a nested reverse transcriptase–PCR was
performed. As shown in Fig 4(a), mRNA for eotaxin (upper panel)
and its receptor CCR3 (middle panel) could be detected by nested
reverse transcriptase–PCR in lesional (n 5 6) and nonlesional
(n 5 6) AD skin, whereas mRNA encoding these two molecules
were hardly or not detectable in normal skin of nonatopic controls
(n 5 6). The specificity of the PCR products was confirmed by
sequence analysis (data not shown). PCR amplification of β-actin
mRNA after 20 cycles is shown as a positive control for equivalent
loading and integrity of the RNA used in the analyses (Fig 4a,
lower panel). Negative controls, including water blanks (Fig 4b,
lane 1) and RNA extracted from the melanoma SB-1 cell line
revealed no amplification signals (lane 2) in contrast to a lesional
skin sample from AD (lane 3). Furthermore, no signals were found
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Figure 3. Eotaxin and CCR3 immunoreactivity in NS, NL, and LS.
(A) Eotaxin; (B) CCR3; NS, n 5 5; NL, n 5 7; LS, n 5 7. Mean 6 SEM.
Statistical analysis (Mann–Whitney U-test) is indicated.
in samples without reverse transcriptase reaction (lane 4 and 5)
excluding DNA contamination. In three patients with AD, eotaxin
transcripts were also detected by a standard reverse transcriptase–
PCR analysis (data not shown) indicating particularly high mRNA
levels in the skin of these patients.
Semi-quantitative analysis of the transcripts by densitometric
scanning and determination of the relative amounts of eotaxin and
CCR3 are shown in Fig 5. A mean increase of 110-fold for eotaxin
(p , 0.05) and of 40-fold for CCR3 (p , 0.05) mRNA was
found in lesional, as compared with normal skin. Furthermore, a
significant mean increase of 25-fold for eotaxin (p , 0.05) and of
36-fold for CCR3 (p , 0.05) mRNA was also detected in
nonlesional skin, compared with normal skin.
DISCUSSION
In this study we demonstrated, that eotaxin and CCR3 levels
assessed by immunostaining and reverse transcriptase–PCR are
markedly increased in lesional skin from AD as compared with
normal skin from nonatopic controls. Both CCR3 immuno-
reactivity and mRNA levels as well as eotaxin mRNA levels were
also significantly enhanced in nonlesional AD skin samples. Whereas
CCR3 immunoreactivity was significantly stronger in lesional than
in nonlesional AD skin, the differences in CCR3 mRNA levels
between these samples, however, were not significant. Furthermore,
although increased messenger levels for eotaxin were also observed
in nonlesional AD skin, immunoreactivity in these samples was
not significantly enhanced as compared with normal skin. Such
differences between the mRNA and protein levels may be a
consequence of translational and post-translational modifications
(Harrison, 1990). One reason is that increased mRNA levels may
Figure 4. Eotaxin and CCR3 mRNA in AD and normal skin. (A)
Nested reverse transcriptase–PCR products of eotaxin (208 bp) and CCR3
(429 bp) in NS (n 5 6) and in NL (n 5 6) and LS (n 5 6) from AD
were detected by ethidium bromide-stained 2% agarose gel. β-actin
transcripts were used as a control for mRNA integrity. M, molecular
weight standards (100 bp ladder). (B) No signals were found in the water
blanks (lane 1), in RNA extracted from SB-1 cells (lane 2) and in samples
without AMV-RT reaction (lanes 4 and 5). Specific transcripts for eotaxin
and CCR3 from LS are shown in lane 3.
not necessarily result in increased expression of proteins as observed
for eotaxin in the nonlesional AD skin samples. It is possible that
eotaxin production is differentially regulated according to the
degree of surrounding inflammation and that additional factors,
which are not present in the microenvironment of nonlesional
AD skin, are necessary to stimulate protein synthesis efficiently.
Furthermore, discrepancy between mRNA and protein levels
of eotaxin and CCR3 may originate from differences in their
degradation, thus also leading to the detected variation of their
expression in the skin.
Enhanced expression of eotaxin and CCR3 together with an
accumulation of eosinophils was recently observed in human nasal
polyps and in the nasal and bronchial airways in allergic rhinitis
and asthma (Ponath et al, 1996b; Gerber et al, 1997; Lamkhioued
et al, 1997; Mattoli et al, 1997; Minshall et al, 1997; Ying et al,
1997). These reports indicate that eotaxin is expressed in resident
cells such as epithelial and endothelial cells as well as mononuclear
cells and eosinophils recruited to the site of inflammation. As
shown in this study, expression of eotaxin in the skin of AD was
mainly observed in mononuclear cells and eosinophils as well
as in fibroblasts, whereas no significant staining was found in
keratinocytes. The latter observation is in accordance with a recent
report by Mochizuki et al (1998) which indicates that cultured
dermal fibroblasts but not keratinocytes produce eotaxin. Further-
more, as observed in human nasal polyps and the bronchial airways
(Gerber et al, 1997; Ying et al, 1997), CCR3 immunoreactive cells
in the skin were predominantly observed on mononuclear cells
and eosinophils in the dermis.
In AD eosinophils are well recognized as important effector cells
in promoting tissue inflammation and inducing tissue damage
through the release of toxic granule proteins, lipid mediators, and
cytokines (Leiferman et al, 1996). Peripheral blood eosinophilia
and in particular serum levels of eosinophil cationic protein were
reported to correlate with the severity of skin disease (Czech et al,
1992). In this study enhanced eotaxin and CCR3 expression was
also found in parallel to increased numbers of eosinophils and
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Figure 5. Eotaxin and CCR3 mRNA in NS, NL, and LS. (A) Eotaxin;
(B) CCR3; NS, n 5 6; NL, n 5 6; LS, n 5 6. Semi-quantitative analysis
of the mRNA levels of eotaxin and CCR3 were estimated using the levels
of β-actin transcripts as internal reference. Mean 6 SEM. Statistical analysis
(Mann–Whitney U-test) is indicated.
deposition of eosinophil granular proteins in the skin lesions of
AD. In addition, a tendency for higher eosinophil blood counts
was observed in the patients with marked expression of eotaxin in
the skin lesions (data not shown). These results indicate that the
recruitment and activation of eosinophils in AD may strongly
depend on eotaxin acting via CCR3. Although other chemokines
can recruit eosinophils, these results suggest a preponderate role for
eotaxin, as expression of MCP-3 and MIP-1α was not significantly
enhanced in the AD lesions.
In recent years compelling evidence has accumulated for a major
involvement of T lymphocytes in the pathogenesis of AD (Leung
et al, 1996; Romagnani, 1996; Grewe et al, 1998). Increased
numbers of T helper lymphocytes with a type 2-cytokine profile
are present, especially at the initial phase of skin inflammation,
whereas both type 2 cytokines (IL-5) and type 1 cytokines
(interferon-γ) are upregulated in chronic lesions (van der Heijden
et al, 1991; van Reijsen et al, 1992; Grewe et al, 1994; Hamid et al,
1994; Ohmen et al, 1995). Recent data indicate that human Th1
and Th2 lymphocytes express distinct chemokine receptors and are
differentially recruited in response to chemokines. Th2 lymphocytes
were shown to express CCR3 preferentially and selectively migrate
in response to eotaxin (Gerber et al, 1997; Sallusto et al, 1997).
Recently, CCR4 and CCR8 were also shown to be expressed on
Th2 lymphocytes (Bonecchi et al, 1998; Zingoni et al, 1998). Besides
influencing eosinophil recruitment and activation, eotaxin may thus
contribute to the selective infiltration of Th2 subsets in lesional as
well as nonlesional AD skin. The attraction of Th2 lymphocytes
to the site of inflammation in AD is of particular relevance as type
2 cytokines, such as IL-4, IL-5, IL-10, and IL-13, were reported
to promote eosinophil activation (Leiferman et al, 1996).
Furthermore, IL-4 as well as other proinflammatory cytokines like
IL-1, tumor necrosis factor-α and interferon-γ may stimulate the
production of eotaxin (Bartels et al, 1996; Lilly et al, 1997;
Mochizuki et al, 1998). In addition, IL-5 was recently shown to
induce CCR3 on eosinophils (Tiffany et al, 1998). IL-5 is known
to be upregulated in chronic AD skin lesions and may therefore
lead to an increased CCR3 expression on lymphocytes and granulo-
cytes. Intriguingly, a marked enhancement of CCR3 mRNA and
immunoreactivity was also detected in nonlesional AD skin as
compared with normal skin. This finding is of particular interest,
as activation of CCR3-positive cells especially in nonlesional AD
skin may trigger the development of eczematous lesions. As shown
by the analysis of consecutive sections, the pattern of eotaxin and
CCR3 immunoreactivity partly corresponded to that of CD31
cells, indicating that in AD T lymphocytes may express eotaxin
and CCR3. Thus a positive feedback loop appears to amplify
preferentially the chemotactic response of Th2 lymphocytes. Double
immunostaining experiments to identify precisely the cell types
producing eotaxin and CCR3 in the skin, however, were not
feasible and the phenotype of the T lymphocyte population
expressing eotaxin and CCR3 at the inflammatory site in the
dermis remains to be determined in future studies.
Together our data show that the expression of eotaxin and
CCR3 is upregulated in AD. Eotaxin–CCR3 interaction is likely
to represent a major mechanism for promoting tissue inflammation
and indicates that CCR3 antagonists are potential candidates for
immunotherapy in AD.
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